Older People’s Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment

Decalf, Veerle; Huion, Anja; Benoit, Dries F.; Denys, Marie‐Astrid; Petrovic, Mirko; Everaert, Karel

doi:10.1007/s40266-017-0474-6

Cited by 29 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40,58,60,65,84 All seven discrete choice experiments and the traditional conjoint analysis used additional choice scenarios to test the participants' understanding of the task as well as the consistency of their answers. 51,64,79,80,[85][86][87][88] One study targeted criterion validity by inquiring the patients' satisfaction with the treatment that was selected based on the results of the preference elicitation. 48 Nine studies applied qualitative research to aid the interpretation of the quantitative results of the respective preference task.…”

Section: Methods To Assess Patient Preferencesmentioning

confidence: 99%

“…Thirty-nine studies met our age-related eligibility criteria by exclusively including adults aged 65 years and older, 32,35,[37][38][39]41,42,[44][45][46][49][50][51][52][53][54][55][56][57][58][59][60][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78] 16 by reporting a mean or median age ≥ 75 years, 31,36,40,43,47,48,61,[79][80][81][82]…”

Section: Study Populationsmentioning

confidence: 99%

“…42,47,49,51,52,54,56,57,71,74,79 Thirty-seven studies reported data regarding the cognitive status of their participants. 31,32,35,36,[41][42][43][44]47,49,[51][52][53][55][56][57][58][59][60][61][63][64][65][66][67][68][69][70][71][72]74,75,78,80,83,84,90 In 83.8 % of these studies Variety of pharmacological aspects represented by the method ▼ Low: Method elicits preferences for < 5 different pharmacological aspects (health outcomes, treatment options or procedural characteristics) ▬ Intermediate: Method elicits preferences for 5-10 different pharmacological aspects (health outcomes, treatment options or procedural characteristics) ▲ Hi...…”

Section: Study Populationsmentioning

confidence: 99%

See 2 more Smart Citations

<p>Methods to Assess Patient Preferences in Old Age Pharmacotherapy – A Systematic Review</p>

Eidam¹,

Roth²,

Lacroix³

et al. 2020

PPA

View full text Add to dashboard Cite

Purpose: The aim of this systematic review was to identify methods used to assess medication preferences in older adults and evaluate their advantages and disadvantages with respect to their applicability to the context of multimorbidity and polypharmacy. Material and Methods: Three electronic databases (PubMed, Web of Science, PsycINFO) were searched. Eligible studies elicited individual treatment or outcome preferences in a context that involved long-term pharmacological treatment options. We included studies with a study population aged ≥ 65 years and/or with a mean or median age of ≥ 75 years. Qualitative studies, studies assessing preferences for only two different treatments, and studies targeting preferences for life-sustaining treatments were excluded. The identified preference measurement methods were evaluated based on four criteria (time budget, cognitive demand, variety of pharmacological aspects, and link with treatment strategies) judged to be relevant for the elicitation of patient preferences in polypharmacy. Results: Sixty articles met the eligibility criteria and were included in the narrative synthesis. Fifty-five different instruments to assess patient preferences, based on 24 different elicitation methods, were identified. The most commonly applied preference measurement techniques were "medication willingness" (description of a specific medication with inquiry of the participant's willingness to take it), discrete choice experiments, Likert scale-based questionnaires, and rank prioritization. The majority of the instruments were created for disease-specific or context-specific settings. Only three instruments (Outcome Prioritization Tool, a complex intervention, "MediMol" questionnaire) dealt with the broader issue of geriatric multimorbidity. Only seven of the identified tools showed somewhat favorable characteristics for a potential use of the respective method in the context of polypharmacy. Conclusion: Up to now, few instruments have been specifically designed for the assessment of medication preferences in older patients with multimorbidity. To facilitate valid preference elicitation in the context of geriatric polypharmacy, future research should focus on suitable characteristics of existing techniques to develop new measurement approaches for this increasingly relevant population.

show abstract

Section: Methods To Assess Patient Preferencesmentioning

confidence: 99%

Section: Study Populationsmentioning

confidence: 99%

Section: Study Populationsmentioning

confidence: 99%

See 1 more Smart Citation

<p>Methods to Assess Patient Preferences in Old Age Pharmacotherapy – A Systematic Review</p>

Eidam¹,

Roth²,

Lacroix³

et al. 2020

PPA

View full text Add to dashboard Cite

show abstract

“…The invention of novel small molecules that are both potent and selective antitumor agents continues to be a serious challenge to medicinal chemistry researchers (Zhong et al, 2014;Iyer, 2015;Lin et al, 2019). In spite of the indispensable advances accomplished over the last decades in the design and development of assorted anticancer agents, current accessible treatments still have two significant limitations, the primary being the shortage of selectivity for cancer tissues (Shafei et al, 2017), inflicting unwanted side effects (Cavero-Redondo et al, 2015;Brewer et al, 2016;Decalf et al, 2017). The second is the acquisition of multiple-drug resistance by cancer cells, rendering them unresponsive to standard therapy (Wu et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors

et al. 2020

View full text Add to dashboard Cite

EGFR and VEGFR-2 represent promising targets for cancer treatment as they are very important in tumor development as well as in angiogenesis and metastasis. In this work, 6-amino-4-(2-bromophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile 1 and (E)-4-(2-Bromobenzylidene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one 11 were selected as starting materials to synthesize different fused pyrazole derivatives; dihydropyrano[2,3-c]pyrazole 1, 2, 7-9, and 15, pyrazolo[4 ′ ,3 ′ :5,6]pyrano[2,3d]pyrimidine 3-6, pyrazolo[3,4-d]pyrimidine 12 and 13, and pyrazolo[3,4-c]pyrazole 14 derivatives were synthesized to evaluate their anticancer activity against HEPG2 human cancer cell lines compared to erlotinib and sorafenib as reference drugs. Seven compounds 1, 2, 4, 8, 11, 12, and 15 showed nearly 10 fold higher activity than erlotinib (10.6 µM) with IC 50 ranging from 0.31 to 0.71 µM. In vitro EGFR and VEGFR-2 inhibitory activity were performed for the synthesized compounds, and the results identified compound 3 as the most potent EGFR inhibitor (IC 50 = 0.06 µM) and compound 9 as the most potent VEGFR-2 inhibitor (IC 50 = 0.22 µM). Moreover, compounds 9 and 12 revealed potent dual EGFR and VEGFR-2 inhibition, and these results were supported by docking studies of these two compounds within the active sites of both enzymes.

show abstract

“…Patient preferences and trade-offs for OAB therapies have been quantitatively assessed among individuals with OAB; 6 – 8 however, little is known on how treatment preferences change based on severity of OAB or other clinical and patient characteristics. Although past discrete choice experiments (DCEs) have included a mix of treated and untreated patients, 6 , 8 specific preferences among treatment-naïve patients have not been examined. 5 Furthermore, previous DCEs on patient preferences for OAB therapies have been conducted in Europe and the United Kingdom, 6 – 8 and applicability of these results to other countries is unknown.…”

Section: Introductionmentioning

confidence: 99%

A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US

Athavale¹,

Gooch²,

Walker³

et al. 2018

PPA

View full text Add to dashboard Cite

PurposeMany pharmacotherapeutic treatment options are available for the symptoms of overactive bladder (OAB), each offering varying efficacy, safety, and tolerability profiles that must be carefully considered when selecting treatment. The objective of the present study was to characterize pharmacotherapy treatment preferences of individuals with symptoms of OAB and to examine how preferences differ by both patient characteristics and disease burden metrics.Patients and methodsPatient preferences for OAB treatment attributes were examined using a discrete choice experiment (DCE). Attributes were identified through literature review, clinical relevance, and input from patients. Eligible respondents were required to be ≥18 years of age, have a self-reported physician OAB diagnosis or have self-reported symptoms of OAB, and be naïve to pharmacotherapy or invasive OAB treatments. A hierarchical Bayesian random-effects-only model was used to estimate the mean relative preference weights and mean relative importance scores of treatment attributes. Multivariable linear regression models with backward selection were used to analyze the differences in relative importance scores by demographic characteristics and disease burden-related metrics.ResultsIn total, 514 individuals participated in the study. Most respondents were <65 years of age (66.0%), female (68.5%), and reported moderate/severe OAB symptoms (64.2%). Overall, respondents placed the greatest importance on drug delivery method, with a preference for oral and patches over injectables, followed by efficacy defined as reduced daytime micturition and out-of-pocket cost. Multivariable linear regression analyses revealed that females were less likely to select injectables, that symptom control of incontinence was the most important to respondents who reported greater work productivity loss, and that out-of-pocket cost was the most important to respondents with moderate/severe OAB.ConclusionOAB treatment preferences vary depending on individual patient characteristics and disease severity. Overall, drug delivery method, reduced daytime micturition, and out-of-pocket costs were the most important treatment attributes among treatment-naïve individuals with symptoms of OAB. Preferences for OAB treatment were also found to vary depending on patient demographics and disease comorbidities, which has previously not been examined.

show abstract

Older People’s Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment

Abstract: Older people attribute more importance to loss of cognitive function as a possible side effect of antimuscarinic treatment than to the three most prevalent possible side effects of this treatment.

Cited by 29 publications

References 34 publications

<p>Methods to Assess Patient Preferences in Old Age Pharmacotherapy – A Systematic Review</p>

<p>Methods to Assess Patient Preferences in Old Age Pharmacotherapy – A Systematic Review</p>

Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors

A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US

Contact Info

Product

Resources

About

Older People’s Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment

Abstract: Older people attribute more importance to loss of cognitive function as a possible side effect of antimuscarinic treatment than to the three most prevalent possible side effects of this treatment.

Cited by 29 publications

References 34 publications

<p>Methods to Assess Patient Preferences in Old Age Pharmacotherapy – A Systematic Review</p>

<p>Methods to Assess Patient Preferences in Old Age Pharmacotherapy – A Systematic Review</p>

Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors

A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-na&iuml;ve overactive bladder patients in the US

Contact Info

Product

Resources

About

A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US